Connect Biopharma is uncoupling from Pfizer, returning the rights to an eczema candidate it picked up in 2012 to free up cash to advance its two lead programs.
Reported two positive readouts for rademikibart, the Company's lead asset, from the Global Phase 2b trial in moderate-to-severe persistent asthma and from the China pivotal trial in moderate-to-severe...
SAN DIEGO and TAICANG, China, March 19, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a global clinical-stage biopharmaceutical...
James Huang brings over 30 years of biotech experience as a successful entrepreneur, investor and key opinion leader in the healthcare sector SAN DIEGO, CA and TAICANG, China, Feb. 12, 2024 (GLOBE...
James Huang brings over 30 years of biotech experience as a successful entrepreneur, investor and key opinion leader in the healthcare sector SAN DIEGO, CA and TAICANG, China, Feb. 12, 2024 (GLOBE...
Rigel Announces Collaboration with CONNECT to Conduct Phase 2 of Olutasidenib
The global trial met its primary endpoint showing both doses of rademikibart treatment significantly improved lung function at Week 12The significant improvement in lung function was observed as early...
A few weeks after selling off certain regional rights to monoclonal antibody (mAb) rademikibart, Connect Biopharma is back to share that the mid-stage asthma trial assessing the candidate has hit its main goal, demonstrating significantly improved lung function.
SAN DIEGO, CA and TAICANG, China, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (œConnect Biopharma or the œCompany), a global clinical-stage...
Clinical response (IGA 0/1 and EASI-75) achieved at Week 16 with rademikibart treatment was maintained through Week 52 with both every two weeks (Q2W) and every four weeks (Q4W) dosing regimens...